Key result
Leadless pacemaker technology for right ventricular stimulation and resynchronization therapy remains a promising option that currently lacks support from randomized clinical trials.
Leadless pacing is a reality for specific indications, and its use for resynchronization therapy remains a promising niche option pending randomized trials.
Leadless stimulation of the right ventricle is now a reality, especially in patients with very specific indications and clinical characteristics, even in the absence of randomized studies to support its use. The reduction of device costs and the refinement of atrioventricular synchronization algorithms will sanction its greater diffusion in the future. The possibility of using leadless technology also for resynchronization therapy, on the other hand, is currently a promising option but, pending randomized studies with robust case histories and adequate follow-ups, it should still be considered as a niche therapy, to be limited to centres highly specialized and in patients in whom conventional resynchronization has been impossible or ineffective.
No takes yet. Share an insight, caveat, or question.
F Stazi (2021) conducted a review in Need for right ventricular stimulation or resynchronization therapy. Leadless pacemaker was evaluated. Leadless pacemaker technology for right ventricular stimulation and resynchronization therapy remains a promising option that currently lacks support from randomized clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: